Blocking Biosimilars
As the U.S. Food and Drug Administration (FDA) continues to finalize regulations
to establish a pathway for approving biopharmaceutical or biosimilar drugs,
leading branded drug manufacturers are looking ahead and lobbying state
legislatures to enact laws that would limit the substitution of biogenerics for
brand-name drugs. Currently, pharmacists in most states can substitute
lower-cost generics for branded chemical or small-molecule drugs without such
approval.
BY WORLD DRUG TRACKER
No comments:
Post a Comment